Ondine Biopharma Corporation
TSX : OBP
AIM : OBP

Ondine Biopharma Corporation

March 12, 2009 12:28 ET

Successful MRSA Wound Disinfection Study Announced by Ondine

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 12, 2009) - Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP) (the "Company") today announced publication of a study demonstrating the first successful decontamination of heavily MRSA-infected wounds in animals. The study was carried out by a team of collaborative researchers at the University College London, UK, and utilized Ondine's MRSAid™ photodisinfection system which is currently under development.

"The MRSAid™ photodisinfection system builds upon our successful Periowave™ technology for treatment of periodontal disease," stated Dr. Cale Street, Ondine's Vice President of Research. "The MRSAid™ system was designed to rapidly decolonize the noses of patients carrying the MRSA superbug, reducing the rate of MRSA transmission by a patient to their own surgical incisions as well as to other patients and healthcare workers. In this published work, a team of internationally recognized researchers demonstrated for the first time in vivo photodynamic elimination of the epidemic strain of MRSA that is now unfortunately so common in the UK and elsewhere."

"This work is important for several reasons," stated Professor Michael Wilson, Division of Microbial Disease, University College London. "For one, it is a completely novel approach to disinfection of burns and wounds contaminated with the potentially lethal MRSA bacterium. Second, photodynamic disinfection is very unlikely to generate resistance to the treatment that commonly occurs when antibiotics are used. The treatment stays effective time after time. And third, perhaps most important, the treatment is fast. This does not require a course of antibiotics lasting days or weeks. In this study, we were able to reduce MRSA counts by 25-fold in only 30 minutes despite the presence of blood, serum and other wound exudates - with no negative side effects. We look forward to seeing this breakthrough technology deployed in our hospitals, nursing homes and other institutions as a first line of defense against this alarming pathogen."

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.

For further information about the study referred to above, please see BMC Microbiology 2009, 9:27.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information